pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Symbravo
drug
save

(meloxicam + rizatriptan benzoate)

Marketedupdated 3mo ago
by $AXSM Axsome Therapeutics, Inc.
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 30, 2028
~1.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (82)

  • Mar 10, 2045method-of-use (U-1719)US 12544383
  • Dec 29, 2041method-of-use (U-1719)US 12370196
  • May 28, 2040method-of-use (U-1719)US 12128052
  • May 28, 2040method-of-use (U-1719)US 12551488
  • May 28, 2040method-of-use (U-1719)US 12551489
  • May 18, 2038method-of-use (U-4356)US 12472256
  • May 18, 2038method-of-use (U-4134)US 12472257
  • May 18, 2038formulationUS 12472258
  • Apr 11, 2036method-of-use (U-4133)US 10029010
  • Apr 11, 2036formulationUS 10058614
  • Apr 11, 2036formulationUS 10137131
  • Apr 11, 2036method-of-use (U-1719)US 10195278
  • Apr 11, 2036method-of-use (U-1719)US 10265324
  • Apr 11, 2036method-of-use (U-1719)US 10363312
  • Apr 11, 2036method-of-use (U-4134)US 10369224
  • Apr 11, 2036method-of-use (U-4135)US 10426839
  • Apr 11, 2036formulationUS 10463736
  • Apr 11, 2036method-of-use (U-1719)US 10471014
  • Apr 11, 2036method-of-use (U-1719)US 10471069
  • Apr 11, 2036method-of-use (U-1719)US 10512692
  • Apr 11, 2036method-of-use (U-1719)US 10512693
  • Apr 11, 2036method-of-use (U-1719)US 10517950
  • Apr 11, 2036method-of-use (U-1719)US 10532101
  • Apr 11, 2036method-of-use (U-1719)US 10537642
  • Apr 11, 2036method-of-use (U-1719)US 10561664
  • Apr 11, 2036method-of-use (U-1719)US 10583144
  • Apr 11, 2036method-of-use (U-1719)US 10653777
  • Apr 11, 2036method-of-use (U-1719)US 10688102
  • Apr 11, 2036method-of-use (U-1719)US 10688185
  • Apr 11, 2036method-of-use (U-1719)US 10695429
  • Apr 11, 2036method-of-use (U-1719)US 10695430
  • Apr 11, 2036method-of-use (U-4136)US 10702535
  • Apr 11, 2036method-of-use (U-1719)US 10702602
  • Apr 11, 2036method-of-use (U-1719)US 10722583
  • Apr 11, 2036method-of-use (U-1719)US 10729696
  • Apr 11, 2036method-of-use (U-1719)US 10729697
  • Apr 11, 2036method-of-use (U-1719)US 10729773
  • Apr 11, 2036method-of-use (U-1719)US 10758617
  • Apr 11, 2036method-of-use (U-1719)US 10758618
  • Apr 11, 2036method-of-use (U-1719)US 10780165
  • Apr 11, 2036method-of-use (U-1719)US 10780166
  • Apr 11, 2036method-of-use (U-1719)US 10799588
  • Apr 11, 2036method-of-use (U-1719)US 10821181
  • Apr 11, 2036method-of-use (U-1719)US 10821182
  • Apr 11, 2036method-of-use (U-1719)US 10894053
  • Apr 11, 2036method-of-use (U-1719)US 10905693
  • Apr 11, 2036method-of-use (U-1719)US 10918722
  • Apr 11, 2036method-of-use (U-1719)US 10933136
  • Apr 11, 2036method-of-use (U-1719)US 10933137
  • Apr 11, 2036method-of-use (U-1719)US 10940153
  • Apr 11, 2036method-of-use (U-1719)US 10987358
  • Apr 11, 2036method-of-use (U-1719)US 11013805
  • Apr 11, 2036method-of-use (U-1719)US 11013806
  • Apr 11, 2036method-of-use (U-1719)US 11020483
  • Apr 11, 2036method-of-use (U-1719)US 11045549
  • Apr 11, 2036method-of-use (U-1719)US 11135295
  • Apr 11, 2036method-of-use (U-1719)US 11207328
  • Apr 11, 2036method-of-use (U-1719)US 11219626
  • Apr 11, 2036method-of-use (U-1719)US 11285213
  • Apr 11, 2036method-of-use (U-1719)US 11331323
  • Apr 11, 2036method-of-use (U-1719)US 11369684
  • Apr 11, 2036method-of-use (U-1719)US 11426414
  • Apr 11, 2036method-of-use (U-1719)US 11471464
  • Apr 11, 2036method-of-use (U-1719)US 11471465
  • Apr 11, 2036method-of-use (U-1719)US 11504429
  • Apr 11, 2036method-of-use (U-1719)US 11510927
  • Apr 11, 2036method-of-use (U-1719)US 11571428
  • Apr 11, 2036method-of-use (U-1719)US 11602563
  • Apr 11, 2036method-of-use (U-1719)US 11607456
  • Apr 11, 2036method-of-use (U-1719)US 11617755
  • Apr 11, 2036method-of-use (U-1719)US 11617756
  • Apr 11, 2036method-of-use (U-1719)US 11617791
  • Apr 11, 2036method-of-use (U-1719)US 11628173
  • Apr 11, 2036method-of-use (U-1719)US 11712441
  • Apr 11, 2036method-of-use (U-1719)US 11738085
  • Apr 11, 2036method-of-use (U-1719)US 11759522
  • Apr 11, 2036method-of-use (U-1719)US 11801250
  • Apr 11, 2036method-of-use (U-1719)US 11806354
  • Apr 11, 2036method-of-use (U-1719)US 11826370
  • Apr 11, 2036method-of-use (U-1719)US 11865117
  • Apr 11, 2036method-of-use (U-4133)US 12485176
  • Apr 11, 2036formulationUS 9821075

FDA exclusivities (1)

  • Jan 30, 2028NPNP1.4y

News(0)

no news has mentioned this drug yet

brand
Symbravo
generic
(meloxicam + rizatriptan benzoate)
indication
Migraine
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 21m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?